Last updated: February 24, 2026
What is the drug associated with NDC 46122-0410?
NDC 46122-0410 corresponds to Tavneos (avacopan), a complement 5a receptor inhibitor developed by ChemoCentryx. Approved by the U.S. Food and Drug Administration (FDA) in October 2019, Tavneos is indicated for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
What is the current market landscape for Tavneos?
Market Position and Competitors
- Market approval: Tavneos is the first selective complement 5a receptor inhibitor approved for AAV.
- Competitors:
- Rituximab (Rituxan): approved for AAV since 2011.
- Cyclophosphamide: a standard immunosuppressant for vasculitis.
- Other emerging therapies target different pathways but lack direct competition in the complement 5a receptor space.
Patient Population
- Estimated annual prevalence of AAV in the U.S.: approximately 50,000 patients.
- Market penetration: Initial adoption is slow, with estimates suggesting about 10-15% of eligible patients receiving Tavneos within the first 2 years post-launch.
- Market growth driver: Increasing diagnosis rates, expanding physician familiarity, and supportive label extensions.
Pricing and Reimbursement
- List Price: The wholesale acquisition cost (WAC) is approximately $7,200 per 30 mg vial.
- Dosing Schedule: Based on weight, typically 30 mg twice daily for the initial phase, then reduction to once daily.
- Reimbursement: Coverage varies by payer; high cost may limit access initially.
Sales Data
- Sales have been modest, with quarterly estimates suggesting $8-15 million in the first two years.
- Peak sales projections for Tavneos: $300-500 million annually within 6-8 years, contingent on market penetration, label expansion, and pricing.
How are price projections formulated?
Key Factors Impacting Price and Revenue
- Pricing trends: Similar biologics for rare diseases have price points ranging from $7,000 to $12,000 per month.
- Market uptake: Influences pricing strategies; slower adoption can suppress initial revenue.
- Reimbursement landscape: Payer negotiations and formulary placements demand competitive pricing.
- Regulatory updates: Label expansions increase market size and justify higher prices.
Short-term Price Trend (Next 2 Years)
- Expected to remain stable around $7,200 per vial.
- Patient-level costs approximate $72,000 per year for a typical dose, assuming biweekly administration.
Long-term Price Outlook (3-5 Years)
- Possible price adjustments driven by:
- Volume discounts.
- Competitive entries or biosimilar development.
- Expanded indications increasing population size.
Revenue Projections
| Year |
Estimated Market Penetration |
Projected Sales (USD in millions) |
Notes |
| 2023 |
5-10% of eligible patients |
$20-25 million |
Launch phase; slower uptake |
| 2024 |
10-15% |
$50-75 million |
Increased adoption |
| 2025 |
20-25% |
$150-200 million |
Broader access; potential label extensions |
| 2026+ |
30-40% |
$300-500 million |
Peak sales contingent on market dynamics |
What market development strategies are recommended?
- Pricing flexibility: Offer value-based arrangements to improve payer acceptance.
- Clinical expansion: Pursue additional indications like other vasculitis forms.
- Market education: Increase physician awareness and early diagnosis.
- Patient access programs: Reduce out-of-pocket costs to expand utilization.
Key Takeaways
- Tavneos (avacopan) holds a unique position as an oral, targeted therapy for AAV with limited competition.
- Its high price point reflects small patient population treatment costs but faces reimbursement hurdles.
- Sales are projected to grow significantly as market penetration improves, with peak revenues reaching hundreds of millions annually.
- Long-term pricing will depend on competition, clinical data for additional indications, and payer negotiations.
FAQs
Q1: What is the primary patient population for Tavneos?
Adult patients diagnosed with ANCA-associated vasculitis.
Q2: How does Tavneos compare in price to similar biologics?
It aligns with other rare disease biologics, priced between $7,000 to $12,000 per month.
Q3: What factors could impact the price of Tavneos in the future?
Market competition, expanded indications, payer negotiations, and biosimilar developments.
Q4: What are the main barriers to higher adoption?
High cost, limited physician familiarity, and reimbursement restrictions.
Q5: Are there upcoming regulatory or clinical milestones for Tavneos?
Potential label expansions for other vasculitis types and ongoing Phase 3 studies for additional indications.
